Product news

Share this article:
Sanofi-Aventis and Bristol-Myers Squibb said the FDA Administration has approved a supplemental new drug application for a 300 mg tablet of the antiplatelet drug Plavix (clopidogrel bisulfate). The Plavix 300 mg tablet will facilitate the use of the FDA approved loading dose for appropriate acute coronary syndrome patients as soon as possible after hospital admission.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.